ONCS [NASD]
OncoSec Medical Incorporated
Index- P/E- EPS (ttm)-1.06 Insider Own0.10% Shs Outstand39.31M Perf Week5.95%
Market Cap28.03M Forward P/E- EPS next Y-0.79 Insider Trans-1.77% Shs Float17.27M Perf Month-25.00%
Income-41.00M PEG- EPS next Q-0.18 Inst Own15.70% Short Float1.56% Perf Quarter-23.15%
Sales- P/S- EPS this Y46.30% Inst Trans4.73% Short Ratio3.04 Perf Half Y-53.82%
Book/sh0.50 P/B1.48 EPS next Y112.40% ROA-81.70% Target Price7.50 Perf Year-81.43%
Cash/sh0.66 P/C1.11 EPS next 5Y- ROE-122.20% 52W Range0.67 - 4.25 Perf YTD-23.00%
Dividend- P/FCF- EPS past 5Y39.00% ROI- 52W High-82.61% Beta2.05
Dividend %- Quick Ratio5.00 Sales past 5Y- Gross Margin- 52W Low10.28% ATR0.08
Employees54 Current Ratio5.00 Sales Q/Q- Oper. Margin- RSI (14)37.23 Volatility8.29% 10.42%
OptionableYes Debt/Eq0.03 EPS Q/Q32.50% Profit Margin- Rel Volume0.16 Prev Close0.73
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume88.88K Price0.74
Recom1.50 SMA20-8.28% SMA50-24.40% SMA200-46.91% Volume14,661 Change0.61%
Mar-08-21Initiated BTIG Research Buy $10
Jul-27-20Initiated Dawson James Buy $10
Nov-07-18Downgrade H.C. Wainwright Buy → Neutral $4 → $1
Feb-09-18Initiated Piper Jaffray Overweight $4
Jul-21-16Resumed Rodman & Renshaw Buy $6
Jul-21-16Reiterated Maxim Group Buy $17 → $5
Jun-16-15Reiterated Maxim Group Buy $60 → $17
Apr-29-22 08:00AM  
Feb-22-22 05:58PM  
Dec-17-21 09:09AM  
Nov-02-21 08:00AM  
Oct-20-21 04:02PM  
Aug-26-21 09:46AM  
Aug-17-21 08:28AM  
Aug-16-21 04:01PM  
Jul-26-21 08:30AM  
Jul-07-21 07:58AM  
Jul-06-21 04:01PM  
Jun-24-21 04:30PM  
Jun-14-21 08:30AM  
May-27-21 08:30AM  
May-17-21 08:30AM  
May-03-21 10:24AM  
Apr-15-21 08:30AM  
Apr-14-21 08:30AM  
Mar-25-21 08:39AM  
Mar-01-21 09:00AM  
Feb-23-21 09:00AM  
Feb-18-21 08:30AM  
Feb-02-21 09:00AM  
04:00AM  
Jan-27-21 09:00AM  
Jan-25-21 04:00PM  
Jan-21-21 08:30AM  
Jan-20-21 04:34PM  
Jan-19-21 09:00AM  
08:30AM  
Jan-08-21 09:00AM  
Dec-10-20 09:00AM  
Dec-03-20 09:00AM  
Nov-30-20 09:17PM  
Nov-24-20 09:00AM  
Nov-18-20 09:00AM  
Nov-09-20 08:36AM  
Nov-05-20 09:00AM  
Nov-03-20 09:00AM  
Oct-29-20 09:10AM  
Oct-12-20 08:30AM  
Oct-06-20 08:30AM  
Aug-27-20 08:30AM  
Aug-25-20 08:30AM  
Aug-17-20 03:18AM  
Aug-16-20 11:55PM  
Aug-14-20 08:42PM  
Aug-10-20 03:30PM  
08:30AM  
Aug-06-20 02:31PM  
Aug-05-20 09:00AM  
Jul-27-20 09:00AM  
Jul-13-20 09:00AM  
Jul-09-20 09:00AM  
Jun-24-20 09:00AM  
Jun-22-20 09:05AM  
Jun-09-20 09:00AM  
Jun-04-20 09:00AM  
Jun-03-20 09:00AM  
May-27-20 09:00AM  
May-21-20 09:00AM  
May-14-20 09:00AM  
May-13-20 09:18AM  
May-06-20 09:00AM  
Apr-21-20 09:00AM  
Apr-20-20 09:00AM  
Apr-06-20 09:00AM  
Mar-20-20 09:00AM  
Mar-17-20 08:30AM  
Mar-11-20 08:30AM  
Mar-09-20 08:30AM  
Feb-11-20 08:30AM  
Feb-10-20 08:30AM  
Feb-07-20 10:53AM  
08:00AM  
Feb-04-20 08:30AM  
Feb-03-20 09:48AM  
08:46AM  
Jan-31-20 08:30AM  
Jan-28-20 08:30AM  
Jan-27-20 11:00AM  
08:30AM  
Jan-21-20 04:30PM  
08:30AM  
Jan-17-20 09:30AM  
Jan-16-20 08:30AM  
Jan-15-20 12:38PM  
Jan-14-20 08:30AM  
Jan-07-20 04:30PM  
Jan-06-20 08:30AM  
Dec-30-19 08:45AM  
Dec-26-19 08:43AM  
08:30AM  
Dec-20-19 03:16PM  
10:03AM  
09:00AM  
Dec-18-19 08:32AM  
Dec-17-19 06:30PM  
Dec-16-19 08:30AM  
Dec-13-19 08:30AM  
OncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company's lead product candidate is ImmunoPulse IL-12 that uses electroporation device to deliver a DNA-encoded interleukin-12 for reversing the immunosuppressive microenvironment in the treated tumor. It is also developing ImmunoPulse IL-12 with KEYTRUDA in patients with advanced melanoma that is in clinical trials collaboration and supply agreement (KEYNOTE-695) and metastatic triple negative breast cancer, which is in Phase II clinical trials (KEYNOTE-890); ImmunoPulse IL-12 and KEYTRUDA in patients with advanced or metastatic melanoma that has completed Phase II clinical trials; and ImmunoPulse IL-12 monotherapy in patients with metastatic melanoma, which has completed the Phase II clinical trials. In addition, the company is developing monotherapy biomarker study in patients with advanced or metastatic TNBC that has completed the Phase II clinical trials; and technology to treat liver, lung, bladder, pancreatic, and other visceral lesions. OncoSec Medical Incorporated has clinical trial collaborations with Merck & Co., Inc. and its subsidiary in connection with the KEYNOTE-695 and KEYNOTE-890 studies; a research collaboration with Duke University's Center for Applied Therapeutics to evaluate TAVO in combination or sequenced with a HER2-plasmid vaccine; a research collaboration with Roswell Park Comprehensive Cancer Center to evaluate the use of Roswell Park's intravital microscopy and enhanced IL-12 DNA-plasmid; and collaboration with Providence Cancer Institute. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. The company was incorporated in 2008 and is headquartered in Pennington, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
DelAversano Robert JVP, FinanceMay 06Sale0.8327422723,542May 06 12:35 PM
DelAversano Robert JVP, FinanceFeb 09Sale0.8840936023,816Feb 11 08:00 PM
DelAversano Robert JVP, FinanceNov 01Sale1.7534360024,225Nov 03 08:00 PM
DALESANDRO MARGARETDirectorAug 23Buy1.8920,00037,80020,000Aug 25 05:31 PM
Zhao YuhangDirectorAug 23Buy1.884,0007,52012,000Aug 24 08:03 PM
Zhao YuhangDirectorAug 20Buy1.948,00015,5208,000Aug 24 08:03 PM
DelAversano Robert JVP, FinanceAug 02Sale2.1841289824,568Aug 03 08:14 PM
Leuthner Brian AInterim CEOJun 28Sale3.1613,61343,017178,387Jun 29 07:42 PM